Feng Cindy, Asbridge Mark, Grant Amy, Liu Lihui, Lyu Guanjie, Hassan Fahima
Department of Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, 5790 University Ave, Halifax, NS, Canada.
Maritime SPOR SUPPORT Unit (MSSU), Halifax, NS, Canada.
Can J Public Health. 2025 Aug 6. doi: 10.17269/s41997-025-01092-8.
To examine trends in opioid toxicity mortality in Nova Scotia and its health zones from 2009 to 2023, focusing on differences between pharmaceutical and non-pharmaceutical opioid-related deaths.
We conducted a population-based study using data on annual opioid toxicity mortality rates from 2009 to 2023, stratified by health zone and opioid type. An interrupted time series (ITS) analysis was applied to assess changes in mortality trends across three pandemic-related periods. Comparisons were made between pharmaceutical and non-pharmaceutical opioid mortality to assess evolving patterns of opioid-related harm.
Opioid toxicity mortality in Nova Scotia declined during the peri-pandemic period (2019-2021) but increased significantly post-pandemic, particularly in non-pharmaceutical opioid-related deaths, which steadily rose after 2021. Pharmaceutical opioid-related deaths remained higher than non-pharmaceutical deaths. Health zone analysis revealed geographic variation: the Central Zone experienced stable pharmaceutical mortality with rising non-pharmaceutical deaths post-pandemic; the Eastern Zone saw higher pharmaceutical mortality pre-pandemic, which declined during the peri-pandemic period, while non-pharmaceutical deaths remained low; the Northern Zone had stable pharmaceutical mortality but rising non-pharmaceutical deaths post-pandemic; and the Western Zone exhibited consistently lower mortality rates across both opioid types.
This study reveals significant shifts in opioid-related mortality trends in Nova Scotia, with a rise in non-pharmaceutical opioid deaths post-pandemic, while pharmaceutical opioids remain a major contributor. Geographic variations across health zones highlight the need for region-specific public health strategies. Ongoing efforts to reduce both pharmaceutical and illicit opioid misuse through harm reduction and improved prescribing practices are crucial.
研究2009年至2023年新斯科舍省及其卫生区域阿片类药物中毒死亡率的趋势,重点关注与制药和非制药阿片类药物相关死亡之间的差异。
我们进行了一项基于人群的研究,使用2009年至2023年按卫生区域和阿片类药物类型分层的年度阿片类药物中毒死亡率数据。应用中断时间序列(ITS)分析来评估三个与大流行相关时期死亡率趋势的变化。比较了制药和非制药阿片类药物死亡率,以评估阿片类药物相关危害的演变模式。
新斯科舍省的阿片类药物中毒死亡率在大流行期间(2019 - 2021年)下降,但在大流行后显著上升,特别是在非制药阿片类药物相关死亡中,2021年后稳步上升。与制药阿片类药物相关的死亡人数仍高于非制药死亡人数。卫生区域分析揭示了地理差异:中部地区制药死亡率稳定,大流行后非制药死亡人数上升;东部地区在大流行前制药死亡率较高,在大流行期间下降,而非制药死亡人数仍然较低;北部地区制药死亡率稳定,但大流行后非制药死亡人数上升;西部地区两种阿片类药物类型的死亡率一直较低。
本研究揭示了新斯科舍省阿片类药物相关死亡率趋势的显著变化,大流行后非制药阿片类药物死亡人数上升,而制药阿片类药物仍然是主要原因。各卫生区域的地理差异凸显了针对特定区域的公共卫生策略的必要性。通过减少危害和改进处方实践,持续努力减少制药和非法阿片类药物的滥用至关重要。